TY - JOUR
T1 - Can we prevent immunogenicity of human protein drugs?
AU - Scott, D. W.
AU - De Groot, A. S.
PY - 2010/1
Y1 - 2010/1
N2 - Monoclonal antibodies have proved to be extremely valuable additions to conventional treatment for rheumatic diseases. However, despite the general trend towards "humanisation", these drugs remain immunogenic in clinical settings, baffling drug developers. In principle, humanised and fully human monoclonal antibodies are "self" immunoglobulins and should be tolerated. In this overview, the factors that may influence this process, the nature of immunogenicity and methods to analyse and modify potential immunogenicity are discussed. Finally, novel approaches to "re-induce" immunological tolerance to these proteins, including gene therapy and the recognition of unique regulatory epitopes, are outlined.
AB - Monoclonal antibodies have proved to be extremely valuable additions to conventional treatment for rheumatic diseases. However, despite the general trend towards "humanisation", these drugs remain immunogenic in clinical settings, baffling drug developers. In principle, humanised and fully human monoclonal antibodies are "self" immunoglobulins and should be tolerated. In this overview, the factors that may influence this process, the nature of immunogenicity and methods to analyse and modify potential immunogenicity are discussed. Finally, novel approaches to "re-induce" immunological tolerance to these proteins, including gene therapy and the recognition of unique regulatory epitopes, are outlined.
UR - http://www.scopus.com/inward/record.url?scp=75749087940&partnerID=8YFLogxK
U2 - 10.1136/ard.2009.117564
DO - 10.1136/ard.2009.117564
M3 - Review article
C2 - 19995750
AN - SCOPUS:75749087940
SN - 0003-4967
VL - 69
SP - i72-i76
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - SUPPL. 1
ER -